The ruthenium complex cis-(dichloro)tetraammineruthenium(III) chloride presents selective cytotoxicity against murine B cell lymphoma (A-20), murine ascitic sarcoma 180 (S-180), human breast adenocarcinoma (SK-BR-3), and human T cell leukemia (Jurkat) tumor cell lines.
The aim of present study was to verify the in vitro antitumor activity of a ruthenium complex, cis-(dichloro)tetraammineruthenium(III) chloride (cis-[RuCl(2)(NH(3))(4)]Cl) toward different tumor cell lines. The antitumor studies showed that ruthenium(III) complex presents a relevant cytotoxic activity against murine B cell lymphoma (A-20), murine ascitic sarcoma 180 (S-180), human breast adenocarcinoma (SK-BR-3), and human T cell leukemia (Jurkat) cell lines and a very low cytotoxicity toward human peripheral blood mononuclear cells. The ruthenium(III) complex decreased the fraction of tumor cells in G0/G1 and/or G2-M phases, indicating that this compound may act on resting/early entering G0/G1 cells and/or precycling G2-M cells. The cytotoxic activity of a high concentration (2 mg mL(-1)) of cis-[RuCl(2)(NH(3))(4)]Cl toward Jurkat cells correlated with an increased number of annexin V-positive cells and also the presence of DNA fragmentation, suggesting that this compound induces apoptosis in tumor cells. The development of new antineoplastic medications demands adequate knowledge in order to avoid inefficient or toxic treatments. Thus, a mechanistic understanding of how metal complexes achieve their activities is crucial to their clinical success and to the rational design of new compounds with improved potency.
Silveira-Lacerda
Elisângela de Paula
Ede P
Laboratório de Genética Molecular e Citogenética, Instituto de Ciências Biológicas-ICB I-Sala 200, Universidade Federal de Goiás-UFG, Campus Samambaia Campus II, Goiânia, Goiás, Brazil. elacerda@icb.ufg.br
Vilanova-Costa
Cesar Augusto Sam Tiago
CA
Hamaguchi
Amélia
A
Pavanin
Luiz Alfredo
LA
Goulart
Luiz Ricardo
LR
Homsi-Brandenburgo
Maria Inês
MI
Dos Santos
Wagner Batista
WB
Soares
Andreimar Martins
AM
Nomizo
Auro
A
D000818:Animals; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy; D002453:Cell Cycle / Q000187:drug effects; D045744:Cell Line, Tumor; D049109:Cell Proliferation / Q000187:drug effects; D003602:Cytotoxicity, Immunologic / Q000187:drug effects; D005260:Female; D006801:Humans; D019169:Jurkat Cells / Q000187:drug effects; D016393:Lymphoma, B-Cell / Q000188:drug therapy; D051379:Mice; D012428:Ruthenium / Q000627:therapeutic use; D017975:Ruthenium Compounds / Q000627:therapeutic use*; D012510:Sarcoma 180 / Q000188:drug therapy
C543901:(dichloro)tetraammineruthenium(III); D000970:Antineoplastic Agents; D017975:Ruthenium Compounds; D012428:Ruthenium